

For Immediate Release

**Alembic Ltd.
Consolidated Results for quarter ended 30.09.2010**

**Revenues up 28 % at Rs 365 crores;
PBT up 72 % at Rs 26.71 crores against Rs. 15.54 crores in PY**

Editors Synopsis

- **Net sales up 28 % at Rs 365 crores against Rs. 286 crores in corresponding quarter last year**
- **Domestic Branded formulations up 27% at Rs. 207 crores against Rs. 163 crores in corresponding quarter last year**
- **Total API sales up 33 % at Rs. 100 crores against Rs. 75 crores in corresponding quarter last year**
- **International Generics up by 10 % to Rs. 40 crores vis-à-vis Rs. 36 crores last year**
- **Profit before tax up by 72 % at Rs. 26.71 crores against Rs. 15.54 crores in corresponding quarter in PY**
- **Cumulative ANDA filings at 31, Cumulative DMF filings at 39**

Vadodara, 19th October, 2010

Alembic Limited, the pharmaceutical major, today reported a 28% increase in revenues to Rs 365.42 crores for the quarter ended 30th September 2010, compared to Rs 285.99 crores in the corresponding quarter last year. The Company posted an impressive 72% growth in net profit at Rs. 26.71 crores for the quarter ended September 2010 against Rs 15.54 crores posted in corresponding quarter last fiscal.

Domestic Formulation Business

Domestic formulations posted sales of Rs. 206.83 crores against Rs. 162.55 crores registering healthy 27.42% growth over the corresponding quarter of the previous year.

Alembic has maintained market share of 1.91%. Leading brands like Azithral (26.7%), Wikoryl (29.8%) and Zeet (29.6%) are growing at higher rate than Industry growth. Some of the specialty segments which the company entered recently are showing good progress.

Alembic has five brands in the list of top 300 brands of the industry i.e. 'Azithral', 'Roxid', 'Althrocine', 'Zeet' and 'Wikoryl'.

International Business and API

International Generics to the regulated markets grew by 10% to Rs. 39.79 crores from Rs. 36.14 Crores over the corresponding quarter last year

Domestic API sales recorded a growth of 127% at Rs. 54.65 crores against Rs. 24.12 crores of PY.

Export API recorded sales of Rs. 45.26 crores against Rs. 50.73 crores.

Filings with USFDA till date total 31 ANDAs and 39 DMFs.

Summary of total revenue (consolidated) for the quarter is as under:

(Rs. in Lacs)

Particulars	Consolidated		
	Q2 FY11	Q12FY10	% Change
Formulation			
Domestic	20683	16255	27%
International Branded	1514	1007	50%
International Generics	3979	3614	10
API			
Domestic	5465	2412	127%
International ROW	2309	1864	27
International Regulatory	2217	3209	(-)31
Export Incentives	375	238	58%
Total	36542	28599	28%

The Profit break-up for the quarter is as under:

(Rs. in Lacs)

Particulars	Consolidated		
	Q2 FY11	Q2 FY10	% Change
Operating Income	4410	3494	26%
Profit Before Tax	2671	1554	72%
Net Profit after Tax	2177	1329	64%

About Alembic Limited

Established in 1907, Alembic Ltd. is a leading pharmaceutical company in India. The company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. Alembic is the market leader in Macrolides segment of anti-infective drugs in India.

Alembic's manufacturing facilities are located in Vadodara and Baddi in Himachal Pradesh. The plant at Vadodara has the largest fermentation capacity in India. The Panelav facility houses the API and formulation manufacturing (both US FDA approved) plants. The plant at Baddi, Himachal Pradesh manufactures formulations for the domestic and non-regulated export market. The company has a state of the art Research Centre at Vadodara.

For more information:

Alembic Limited

Mitanshu Shah / Sanjay Bhatt

0265 – 3007630 / 3007853

mitanshu.shah@alembic.co.in / sanjay.bhatt@alembic.co.in